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Introduction. Despite the high number of inactive patients with COPD, not all inactive patients are referred to physical therapy,
unlike recommendations of general practitioner (GP) guidelines. It is likely that GPs take other factors into account, determining
a subpopulation that is treated by a physical therapist (PT). The aim of this study is to explore the phenotypic differences between
inactive patients treated in GP practice and inactive patients treated in GP practice combined with PT. Additionally this study
provides an overview of the phenotype of patients with COPD in PT practice. Methods. In a cross-sectional study, COPD patient
characteristics were extracted from questionnaires. Differences regarding perceived health status, degree of airway obstruction,
exacerbation frequency, and comorbidity were studied in a subgroup of 290 inactive patients and in all 438 patients. Results.
Patients treated in GP practice combined with PT reported higher degree of airway obstruction, more exacerbations, more vascular
comorbidity, and lower health status compared to patients whowere not referred to and treated by a PT.Conclusion. Unequal patient
phenotypes in different primary care settings have important clinical implications. It can be carefully concluded that other factors,
besides the level of inactivity, play a role in referral to PT.
1. Introduction
Physical activity is beneficial for patients suffering from
chronic obstructive pulmonary disease (COPD). Physical
activity can improve symptoms, quality of life, and phys-
ical and emotional participation in everyday activities [1],
whereas a decline from moderate/high physical activity to
low physical activity is associated with an increasedmortality
risk [2]. To describe the number of active or inactive COPD
patients the physical activity norm for healthy persons is
applied as the norm for physical activity in patients with
COPD. To be considered sufficiently physically active, a
healthy adult has to carry out moderate intense physical
activities for at least five days a week, 30minutes a day (Dutch
standard) [3] or 20min of vigorous-intensity physical activity
on at least 3 days every week, or an equivalent combination,
which can also be accumulated in shorter bouts of 10min
exercise (international standard) [3–7]. The extent to which
this framework, on which to base recommendations for
physical activity promotion, applies to patients with COPD
is currently unknown [6]. Since no definite directives are
available about how much physical activity COPD patients
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should carry out, the standard for healthy persons is used in
health care [7].
Epidemiological data show that 84% of patients with
COPD do not reach the Dutch standard for daily physical
activity [8]. Systematic literature reviews conclude that the
number of inactive patients with COPD is some 30% (range
17–43%) higher compared to inactive healthy adults [5, 9–11]
and higher compared to other patients with chronic diseases
like diabetes mellitus and rheumatoid arthritis [12]. Lower
levels of physical activity were already present in the earlier
stages of the disease, and an increasing severity of COPDwas
associated with a further decrease in physical activity [13].
TheDutch general practitioners (GPs) practice guidelines
advice to refer patients with COPD to a physical therapist
(PT) if they do not or cannot comply with theDutch standard
for physical activity due to dyspnoea or fear of dyspnoea [14].
Although inactivity is a referral criterion for physiotherapy,
there is a discrepancy between the numbers of patients
with COPD who are inactive (the earlier mentioned 84%)
and those with COPD treated by a PT (27%) [15]. Indeed,
patients may decide (not) to opt for physical therapy; for
example, patients with COPD perceive their health condition
(dyspnoea) as less severe compared to the objective degree
of severity [16]. However, it is more likely that GPs take
severity of obstruction, symptoms (dyspnoea), exacerbation
risk, and presence of comorbidities into account, besides
inactivity, to refer patients with COPD to physical therapy
[1, 17]. Other patients’ symptoms and perceived level of
limitationsmay additionally play a role in referring patients to
the PT [17]. Patients’ perceptions of limitations are a stronger
predictor of behaviour (like physical activity) than objective
measures of limitation severity [18], as they contribute to
the larger patients’ burden of disease. From a patient per-
spective, COPD can be held responsible for disability that
restricts many everyday activities, such as walking upstairs
[19]. Hence, when assessing the patients’ burden of COPD,
patient reported outcome measures should be incorporated,
for instance, the Clinical COPD Questionnaire (CCQ) that
assesses a broader range of health status than dyspnoea only
[20–22]. We hypothesise that the referral of patients to PT is
based on the patients’ burden of disease and that this is not
necessarily coherent with the level of inactivity.
General practitioner’s considerations to refer to physical
therapy are likely to determine patient flow in primary care.
GPs treat a wide spectrum of patients from less severe to very
severe COPD. PTs however seem to treat a subpopulation of
this spectrum. Although the descriptions of COPD popula-
tions in the literature are limited to in-patients or out-patients
who are under supervision of pulmonary clinics [23, 24],
PTs in primary care settings believe that they are involved
with patients with a high burden of disease. Since physical
therapists are expected to tailor their clinical reasoning and
their choice for exercise therapy to the population that visits
the PT [25], insight in the overall phenotype of their patients
is crucial for PTs. Depending on the level of inactivity but also
depending on other patient characteristics like the presence
of comorbidities [25] and future risk of exacerbations [1],
PTs may have to take into account extensive interdisci-
plinary consultation, adapted training intensity, or longer
treatment duration. We hypothesise that patient phenotypes
are unequal in different primary care settings.
This study explores the phenotypic differences between
inactive patients treated in GP practice and inactive patients
treated in GP practice combined with PT, with regard to
patients’ perceived health status, degree of airway obstruc-
tion, exacerbation frequency, and comorbidity. Additionally
it provides an overview of the overall phenotype of patients
with COPD in PT practice.
2. Methods
2.1. Participants. In 2012, cross-sectional data were collected
in collaboration with ten multidisciplinary primary health
care centres (collaboration “SGE”) providing care to 64,602
people in Eindhoven, Netherlands [26]. In this population,
1,248 patients were diagnosed with COPD, as registered with
code R95 in accordance with the International Classification
of Primary Care (ICPC) in the general practice patient
documentation system. In December 2012, questionnaires
were sent by post to all 1,248 patients.
2.2. Measurements. The questionnaire was developed by
Maastricht University in collaboration with the participat-
ing health centres. It contained items regarding personal
characteristics and disease severity (self-reported). Disease-
related health status was measured with the Clinical COPD
Questionnaire [27], addressing symptoms, functional state,
and mental state (CCQ, rating from 0 “good” to 6 “bad”).
General health status wasmeasured with the first question on
TheShort FormHealth Survey (SF36, rating from 1 “excellent”
to 5 “poor”) [28]. Information regarding physical activity
(Physical Activity questionnaire, rating from0 “not physically
active” to 8 “very physically active”) [29], smoking, and
comorbidities (for 15 different disease categories) was col-
lected. Exacerbation history was measured by an event-based
approach (the number of hospitalisations and medication
intake (0, 1, 2, 3, or 3>)). Whether patients were treated by
a PT for COPD or another health condition was collected
as well. Inactivity was defined as moderate intense physically
active for less than five days a week (30 minutes a day) and
vigorous-intense physically active for less than three days
a week (20 minutes a day) or an equivalent combination.
This corresponds with a score between zero and three on the
Physical Activity questionnaire [7, 29] and is in agreement
with the international standard for physical activity [3–6].
2.3. Data Analyses. From the questionnaires returned, indi-
vidual anonymised data were used. Phenotypic variations in
inactive patients with COPD and in all patients with COPD
treated by a GP versus a PT were analysed, based on the
patient reported outcome measures. The following factors
were treated as categorical data: sex, Global Obstructive
Lung Disease (GOLD stages I–IV) [1], general health status
(SF36), comorbidity (yes or no for 15 different disease cate-
gories), exacerbation frequency (number of hospitalisations
andmedication intake (0, 1, 2, 3, or 3>)), and physical therapy
treatment (yes or no). Age, disease-related health status
(CCQ), physical activity (Physical Activity questionnaire),
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Figure 1: Flowchart of patients registered and treated in pri-
mary care. GP: general practitioner; PT: physical therapist; COPD:
chronic obstructive pulmonary disease. Subgroups in the dotted
boxes were compared for the first aim of this study. Subgroups in
the striped boxes were compared for the second aim of this study.
and smoking history (pack years) were treated as continues
data. Double answers were treated as was specified in the
original questionnaires. If not specified, the less favourable
answer was taken (e.g., “GOLD 3” AND “GOLD 4” were
replaced by GOLD 4; “1-2 days a week physical active” AND
“3-4 days a week physical active” were replaced by 1-2 days
a week; “25 cigarettes a day” AND “15 cigarettes a day” were
replaced by 25 cigarettes).
Between-group differences (GP treatment versus GP
combined with PT treatment) were analysed for the inactive
population and for the whole population by crosstabs with
Pearson 𝜒2 and odds ratios (OR) for sex, GOLD stage,
presence of comorbidity, exacerbation frequency, and general
health perception, with an independent 𝑡-test for age, and
with the Mann-Whitney test for smoking, physical activity,
and disease-related health status.
3. Results
Four hundred and thirty-eight completed questionnaires
were returned, with a response rate of 35%. Missing data was
treated by case wise deletion for each statistical run (41 in
physical activity; 24 in smoking history; 4 in comorbidity; 126
in GOLD stage; 40 in exacerbations; 121 in health status; 42 in
health perception; and 42 in treatment GP versus PT). Data
was sampled independently from the populations being com-
pared, with equal variances. According to the respondents,
eighteen percent of the respondents were treated for COPD
by a PT.Of those patients, 69%were physically inactive. In the
group that did not receive PT, 74% were physically inactive.
Moreover, a total of 73% of patients with COPD registered by
the GP were physically inactive. Figure 1 presents the flow of
patients and the subgroups analysed.
3.1. Phenotype of Inactive Patients in Primary Care. Table 1
presents characteristics of all inactive patients, based on
patient reported outcome measures. Patients who were
referred to PT did not differ significantly from patients
who were treated by a GP only regarding the demographic
characteristics sex (𝜒2(1) = 0.53, 𝑝 = 0.55) and age (𝑡(287) =
−0.36, 𝑝 = 0.72).
Inactive patients treated by GP combined with PT
reported a statistically significant higher degree of airway
obstruction compared to patients treated by a GP only
(𝜒2(3) = 49.10, 𝑝 < 0.0001). Patients with GOLD II or higher
were 9 times more likely to be treated by a PT compared to
patients with GOLD I; for patients with GOLD III or higher
it was 10 times more likely.
Also, higher comorbidity rates were reported in the group
treated by GP combined with PT, but only vascular disease
was significantly more present (𝜒2(1) = 5.77, 𝑝 = 0.020);
those with an additional vascular disease were 2.3 times
more likely to be treated by a PT. Other disease groups, like
neoplasms, musculoskeletal, skin, endocrine, digestive, or
neurological disease, were not statistically different between
the groups. Moreover, these subgroups were very small and
therefore not shown in Table 1.
Significantly higher exacerbation rates were reported by
patients treated by PT (𝜒2(3) = 17.02, 𝑝 = 0.001). The
chance for treatment by a PT increased gradually with higher
exacerbation frequencies (OR = 2.8 with one or more
exacerbations; OR = 3.2 with two or more exacerbations;
OR = 3.3 with three or more exacerbations).
General health perception was significantly lower in the
group treated by PT (𝜒2(2) = 16.44, 𝑝 < 0.0001); those who
rate their general health as poor or moderate were almost
two times more likely to be treated by GP and PT combined.
Comparably, disease-related health status was significantly
lower based on the total CCQ scale (𝑈 = 5762.500, 𝑝 <
0.0001) and based on the subscales for symptoms (𝑈 =
6541.500, 𝑝 = 0.004), functional state (𝑈 = 7904.000, 𝑝 <
0.0001), and mental state (𝑈 = 5016.500, 𝑝 = 0.038).
3.2. Phenotype of Patients in PT Practice. Characteristics of
patients treated by PT versus patients treated by a GP only
can be found in Table 2. All patients (active and inactive) who
received PT did not differ significantly from patients who did
not receive PT regarding the demographic characteristics sex
(𝜒2(1) = 0.71, 𝑝 = 0.45) and age (𝑡(393) = −1.06, 𝑝 = 0.29).
Patients treated by both a GP and a PT reported a
statistically significant higher degree of airway obstruction
compared to patients treated by a GP only (𝜒2(3) = 79.75,
𝑝 < 0.0001). Patients with GOLD II or higher were 15 times
more likely to be treated by a PT compared to patients with
GOLD I.
Also, high comorbidity rates were reported in the group
treated by PT (Table 2), but only vascular disease was
significantly more present (𝜒2(1) = 7.51, 𝑝 = 0.009); those
with an additional vascular disease were 2.7 timesmore likely
to be treated by a PT.
Significantly higher exacerbation rates were shown in
patients treated by PT (𝜒2(4) = 35.91, 𝑝 < 0.0001). The
chance for treatment by a PT increased gradually with higher
exacerbation frequencies (OR = 3.4 with one or more
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Table 1: Characteristics of 290 inactive patients with COPD treated in primary care.
Characteristic Treated by GP only (𝑛 = 236) Treated by GP and PT for COPD (𝑛 = 54) 𝑝 value
Sex, 𝑛male (%) 122 (52) 31 (57) 0.55
Age (yr), mean (SD) 70.29 (11.07) 70.87 (8.76) 0.72
Smoking (pack years), mean (SD) 31.14 (23.54) 40.90 (23.39) 0.001
GOLD stage, 𝑛 (%) <0.0001
I 92 (52) 5 (11)
II 68 (39) 18 (39)
III 10 (6) 15 (33)
IV 6 (3) 8 (17)
Comorbidity, 𝑛 (%)
Cardiovascular 71 (44) 21 (39) 0.317
Cardiac 51 (22) 13 (24) 0.543
Vascular 21 (9) 11 (20) 0.020
Stroke 11 (5) 5 (9) 0.160
Respiratory (asthma) 26 (11) 5 (9) 0.456
Psychological (depression) 32 (14) 5 (9) 0.226
Metabolic (diabetes) 35 (15) 12 (22) 0.137
Nutritional 64 (27) 15 (28) 0.536
Exacerbations in the past year, 𝑛 (%) 0.001
0 127 (54) 16 (30)
1; of which hospitalised 55 (23); 7 (13) 12 (22); 4 (33)
2; of which hospitalised 24 (10); 1 (4) 9 (17); 1 (11)
3 or more; of which hospitalised 29 (12); 15 (52) 17 (32); 8 (47)
Disease-related health status (0–6), mean (SD)
Total CCQ 1.40 (0.95) 1.80 (0.95) <0.0001
Symptoms subscale 1.85 (1.11) 2.35 (1.07) 0.004
Functional state subscale 1.32 (1.14) 2.40 (1.25) <0.0001
Mental state subscale 0.68 (0.99) 0.92 (1.02) 0.038
General health perception (0–5), 𝑛 (%) <0.0001
1, excellent 1 (1) 1 (2)
2, very good 8 (3) 0
3, good 96 (45) 9 (17)
4, moderate 90 (43) 35 (66)
5, poor 17 (8) 8 (15)
GP: general practitioner; PT: physical therapist; SD: standard deviation; GOLD: the Global Initiative for Chronic Obstructive Lung Disease; GOLD stages: I:
mild COPD, FEV1/FVC < 0.7, and FEV1 ≥ 80% of predicted; II: moderate COPD, FEV1/FVC < 0.7, and 50% ≤ FEV1 < 80% of predicted; III: severe COPD,
FEV1/FVC < 0.7, and 30% ≤ FEV1 < 50% of predicted; IV: very severe COPD, FEV1/FVC < 0.7, and FEV1 < 30% of predicted or FEV1 < 50% of predicted plus
chronic respiratory failure; FVC: postbronchodilator forced vital capacity; FEV1: postbronchodilator forced expiratory volume in one second; CCQ: Clinical
COPD Questionnaire: rating from 0 “good” to 6 “bad.”
exacerbations; OR = 3.7 with two or more exacerbations;
OR = 3.8 with three or more exacerbations).
General health perception was significantly lower in the
group treated by PT (𝜒2(2) = 23.71, 𝑝 < 0.0001); those
who rate their general health as poor or moderate were four
timesmore likely to be treated by GP and PT combined. Also,
disease-related health status was significantly lower based on
the total CCQ scale (𝑈 = 11923.000, 𝑝 < 0.0001) and based
on the subscales for symptoms (𝑈 = 13806.500, 𝑝 < 0.0001),
functional state (𝑈 = 16485.000, 𝑝 < 0.0001), and mental
state (𝑈 = 9962.000, 𝑝 = 0.004).
Patients treated by a PTwere significantlymore physically
active in their daily life (𝑈 = 9438.000, 𝑝 = 0.001) but had
a significantly higher history of pack years (𝑈 = 8863.500,
𝑝 = 0.004).
4. Discussion
This study showed that there are phenotypic differences
between patients with COPD in primary care. More specif-
ically, inactive patients treated in GP practice combined
with PT had a higher degree of airway obstruction, more
exacerbations, and more vascular comorbidity and a lower
health status was reported. It may be that patients who are
referred to PT have a higher burden of disease compared to
patients who are not referred to a PT. Moreover, this study
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Table 2: Characteristics of all 438 patients with COPD treated in primary care.
Characteristic All patients
(𝑛 = 438)
Treated by GP only
(𝑛 = 318)
Treated by GP and
PT for COPD
(𝑛 = 78)
𝑝 value
Sex, 𝑛male (%) 235 (54) 166 (52) 45 (58) 0.71
Age (yr), mean (SD) 69 (11) 69 (11) 69 (11) 0.29
Physical activity (0–8), mean (SD) 2.38 (2.31) 2.20 (2.33) 2.92 (1.99) 0.001
Smoking (pack years), mean (SD) 31.14 (23.54) 30.45 (23.30) 38.27 (22.32) 0.004
GOLD stage, 𝑛 (%) <0.0001
I 141 (32) 133 (55) 5 (7)
II 116 (27) 88 (36) 27 (41)
III 35 (8) 14 (6) 21 (32)
IV 20 (5) 7 (3) 13 (20)
Comorbidity, 𝑛 (%)
Cardiovascular 116 (27) 88 (26) 25 (32) 0.171
Cardiac 82 (19) 61 (19) 16 (21) 0.440
Vascular 38 (9) 22 (7) 13 (17) 0.009
Stroke 20 (5) 14 (4) 6 (8) 0.177
Respiratory (asthma) 56 (13) 44 (14) 9 (12) 0.381
Psychological (depression) 60 (14) 44 (14) 10 (13) 0.499
Metabolic (diabetes) 70 (16) 50 (16) 13 (17) 0.469
Nutritional 115 (27) 87 (28) 23 (30) 0.390
Exacerbations in the past year, 𝑛 (%) <0.0001
0 204 (51) 181 (57) 22 (28)
1; of which hospitalised 89 (22); 12 (13) 70 (22); 8 (11) 18 (23); 4 (22)
2; of which hospitalised 47 (12); 4 (9) 32 (10); 3 (9) 14 (18); 1 (8)
3; of which hospitalised 19 (5); 6 (32) 14 (5); 5 (36) 5 (7); 1 (20)
more than 3; of which hospitalised 39 (10); 21 (54) 19 (6); 11 (58) 19 (24); 10 (53)
Disease-related health status (0–6), mean (SD)
Total CCQ 1.51 (1.06) 1.32 (0.97) 2.19 (1.01) <0.0001
Symptoms subscale 1.95 (1.19) 1.76 (1.14) 2.49 (1.13) <0.0001
Functional state subscale 1.52 (1.28) 1.20 (1.13) 2.48 (1.29) <0.0001
Mental state subscale 0.75 (1.06) 0.67 (1.00) 1.02 (1.13) 0.004
General health perception (0–5), 𝑛 (%) <0.0001
1, excellent 6 (2) 4 (1) 1 (1)
2, very good 13 (3) 11 (4) 0
3, good 168 (42) 133 (47) 15 (20)
4, moderate 172 (44) 112 (39) 51 (66)
5, poor 37 (9) 26 (9) 10 (13)
GP: general practitioner; PT: physical therapist; SD: standard deviation; physical activity: rating from 0 “not physically active” to 8 “very physically active”;
GOLD: the Global Initiative for Chronic Obstructive Lung Disease; GOLD stages: I: mild COPD, FEV1/FVC < 0.7, and FEV1 ≥ 80% of predicted; II: moderate
COPD, FEV1/FVC < 0.7, and 50% ≤ FEV1 < 80% of predicted; III: severe COPD, FEV1/FVC < 0.7, and 30% ≤ FEV1 < 50% of predicted; IV: very severe
COPD, FEV1/FVC < 0.7, and FEV1 < 30% of predicted or FEV1 < 50% of predicted plus chronic respiratory failure; FVC: postbronchodilator forced vital
capacity; FEV1: postbronchodilator forced expiratory volume in one second; CCQ: Clinical COPD Questionnaire: rating from 0 “good” to 6 “bad.”
gave an overview of the overall phenotype of patients with
COPD in PT practice. We showed that the group of patients
that were not treated by PT had a low burden of disease
compared to the group of patients treated by a PT. Indeed,
these patients had a double burden of disease (inactive and
significantly more exacerbations) or even a triple burden of
disease (inactive, significantly more exacerbations and more
vascular comorbidity).
Thus, the hypotheses that the referral of patients to PT
is based on the patients’ burden of disease and that this
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is not necessarily coherent with the level of inactivity and
that patient phenotypes are unequal in different primary care
settings were confirmed by the study results.
4.1. Considerations in Patient Referral. Although based on
patient reported data only, this study confirmed that the
majority of patients with COPD are inactive. The large
proportion of patients within PT practice who are inactive
(69%) is not surprising, since GP practice guidelines advise
referring the patient to a PT if the physical activity standard
is not achieved [14]. Interestingly, however, this study showed
also that the group of inactive patients that was not treated by
a PT is extremely large (74%).This can be clarified by different
reasons. A GP might not refer patients to PT when physical
training is not a feasible option. Alternatively, GPs might
consider other patient characteristics needed for referral to
PT than inactivity alone.
Solely based on the inactivity referral criteria, it means
that the GP could have referred more patients to a PT. How-
ever, this statement needs some consideration. According to
the patient reported outcomes, 73% of patients with COPD
registered by the GP were physically inactive, while not more
than 20% were referred to and treated by a PT. On the one
hand, the respondents are a relatively small subgroup (35%)
of the GP population, from which they were recruited. It is
possible that patients who were treated by a PT responded
less often to the questionnaire compared to patients who
were not treated by a PT. However, the National Primary
Care Collaboration LESA reported that 27% of patients with
COPD were referred to a PT in one year [15], which is
a number approximating the patients reported percentage
(20%).
On the other hand, GPs might not have referred inactive
patients to a PT when they showed no unfavourable progno-
sis based on other criteria such as exacerbations, comorbidity,
or limitations in activity. Reversely, by taking into account
these other criteria, GPs might have referred active patients
that showed an overall higher burden of disease. Our findings
confirmed the latter hypothesis, since referred patients to PT
had higher exacerbation rates, more vascular comorbidity,
higher degree of airway obstruction, worse symptom scores
(CCQ-subscale symptoms), more limitation in daily activity
(CCQ-subscale functional state), and lower health perception
(GPE) or health status (CCQ-total scale).
4.2. Clinical Implication of Phenotypic Variation. The pheno-
type of patient populations in different primary care settings
varies. This finding may have several clinical implications.
The results of this study can provide both GPs and PTs
with a realistic perspective fromwhich prior expectations are
set and treatment results are being evaluated. In the light of
(potential) referral criteria, it is useful to understandwhy part
of the inactive patient population is not referred to or treated
by PT.
This study increases GPs awareness of the phenotypes of
patients treated by a PT. Our data also shows that GPs might
deviate from the GP guidelines regarding referral criteria for
good reasons such as disease-related criteriamentioned in the
GOLD report [1]. GPs consider comorbidity as an important
part of COPD management, including referring patients to
a PT. This is a relevant finding, since it is apparent that
COPD clinicians should focus their attention not only on the
management of COPD itself, but also on the investigation and
management of COPD comorbidities [30].
For physical therapists it is important to have insight
into the phenotype of COPD patients who receive PT in
terms of tailoring their clinical reasoning and treatment.This
study showed that PTs, treating patients with COPD, cope
with a patient population that has a relatively higher burden
of disease compared to the patient population treated by a
GP only. This insight is also necessary to improve COPD
care workflows in primary care in order to achieve proactive
maintenance instead of acute rescue in COPD management
[31].
Patients may not seek medical attention until their symp-
toms become troublesome and persistent and significant
respiratory impairment and comorbidities are present [32].
The more severe and complex patient population in the PT
practicemay be one of the reasons that PTs treat patients with
COPD for long-termperiods. Studieswith long-term exercise
programmes for patients with COPD generally achieve more
favourable results regarding functional exercise capacity,
skeletal muscle function, and health-related quality of life
[33]. Although long-term exercise programmes are more
expensive and take more effort for patients, neither health
care insurance companies nor patients are well served by
programmes that yield only modest benefit [33].
Health care insurance companies should bear inmind the
existence of phenotypic variations in their target population
before comparing and judging treatment results across dif-
ferent primary care settings. Patients with COPD who are
treated in PT practices are more complex and may need
longer treatment because of their higher burden of disease
(more exacerbations, more comorbidity, and lower quality
of life). Moreover, health care insurers better not base the
reimbursement for PT in COPD solely on the degree of
airway obstruction (GOLD stage). Parameters that define the
burden of disease and those that can be improved by PT
(as part of pulmonary rehabilitation) should be taken into
account to determine reimbursement policy. Exacerbation
frequency [34, 35], limitations in daily activities [35–37], and
comorbidities, but not necessarily airway obstruction [38],
should be considered as criteria for PT reimbursement [39].
From the patients’ perspective, it seems favourable to
be treated by a PT earlier in the disease process, which
can yield favourable results like higher functional exercise
capacity (walk distance), moremuscle strength, quality of live
(mastery), and daily physical activity (steps) [40]. Referral
to PT should not be delayed until their activity rate has
dropped below threshold (international standard for physical
activity) and their burden of disease is high enough (e.g.,
only patients with a forced expiratory volume in one second
(FEV
1
) of 50% of the predicted or higher are eligible for PT
reimbursement in Netherlands). It is important to assess and
encourage physical activity in the earliest stages of COPD
in order to maintain a physical activity level that is as
high as possible, as this is associated with better prognosis
[2].
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4.3. Limitations of the Study. The response rate in this
study was 35%. Compared to studies that used paper-
based questionnaires that reached response rates within 33–
75% [41], our response rate can be considered relatively
low. Response rates are probably more dependent on the
population sampled than on any other factor [42]. The
questionnaire was combined with multiple questions about
smoking for the benefit of another study. The number of
patients with COPD who did not want to fill out these
specific questions may have reduced the response rate. Since
we are unable to compare the patient characteristics of the
nonrespondentswith the respondents, it is important that our
35% is a representative sample of the base population [41].
The distribution of GOLD stages in this study is comparable
with population-based samples mentioned in international
literature [43]. The percentages of the comorbidities present
in our study correspond relatively well with other COPD
populations [1, 44]. The number of exacerbations is slightly
higher than the populations mentioned by the Global Ini-
tiative for Chronic Obstructive Lung Disease, whereas the
number of hospitalisations is similar per GOLD stage [1].
The respondent characteristics in this study approximate
the characteristics of the COPD population described in
the literature. Nevertheless, the statistical significance of the
specific differences between the subpopulations in this study
needs to be interpreted with care as the external validity can
be compromised [45].
Due to the transversal study design, no causal effect can
be assured for the influence of other referral criteria on the
actual referral by GPs. However, the aim of this study was
to reveal any differences in phenotypes between patients
with COPD treated by PT versus GP only, and this was
answered with the present study design. The demonstrated
higher burden of disease can be seen as a reason for referral
to PT. Indeed, it is less likely that a higher burden of disease
emerges as a consequence of PT, since PT has shown its effect
on reduced hospital admission and mortality and improved
health-related quality of life in COPD in other studies [35].
The higher burden of disease in the group treated by GP
combined with PT was accompanied by the remarkable
lower smoking rate and higher physical activity rate. It is
possible that the physical activity rate was increased after
referral to PT and not vice versa. Some studies showed a
significant increase in daily physical activity after pulmonary
rehabilitation; however other studies did not find an increase
in the level of physical activity [46]. Moreover, once or
twice a week guided therapy for COPD (which includes at
least 30 minutes of moderate exercise) will not necessarily
increase the patient reported physical activity rate per week
to cross the inactivity threshold of the physical activity
standard.
Another limitation might be the use of questionnaires,
introducing potentially social desirable answers. But patient
reported outcome measures cannot be left out when deter-
mining differences between patients’ burdens of disease
in primary care. It has been shown that perceptions of
limitations and reported limitations are a stronger predictor
of behaviour or disease severity than objective measures of
severity [16, 18].
5. Conclusion
General practitioners treat inactive patients with COPD who
are not referred to or treated by a PT. Inactive patients treated
by a GP combined with a PT differ significantly from those
treated by a GP only. The COPD patient population in PT
practices showed a higher burden of disease, regarding higher
exacerbations rates, more vascular comorbidity, more severe
airway obstruction, worse symptoms, more limitations in
daily activity, and, consequently, lower health perception or
health status. Besides the specified inactivity criterion in GP
guidelines, these factorsmayplay a role in the referral to phys-
ical therapy by a GP. These observations have implications
for clinical expectations regarding therapy outcomes, for the
way health care reimbursement for PT is organised and for
generalizability of study results in future research.
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